Business Wire

Hempyre Holdings Ltd. Launches Global Platform for Branded Hemp-Formulated Consumer Packaged Goods

Share

Hempyre Holdings Ltd. (“Hempyre” or the “Company”) is pleased to announce the launch of a global distribution platform of branded hemp-formulated consumer packaged goods focused on beauty, beverage, and wellness.

Headquartered in London, Hempyre has agreed to acquire CMLM Holdings, Inc., dba QIND, a U.S.-based provider of hemp-formulated wellness and beauty products featuring CBD and CBG. Hempyre has also agreed to acquire select beverage and topical brands in the United Kingdom and China and has actively been hiring local executive talent.

Hempyre’s management team is led by Mr. Shannon Soqui, Chief Executive Officer, and Mr. Jason Roth, Chief Strategy Officer. Mr. Soqui was formerly the Chief Executive Officer of QIND, and Mr. Roth was the Co-Founder, Chairman, and Chief Executive Officer of Mile High Labs until October 2019.

Mr. Soqui has 25 years of experience advising and financing emerging growth companies in disruptive markets, including retail and consumer packaged goods. Mr. Soqui has worked exclusively in the cannabis and hemp industry since 2014, after a successful 25-year career in Silicon Valley as an investment banker with firms such as Credit Suisse and UBS, a securities lawyer with Brobeck, Phleger & Harrison, and a CPA with KPMG.

“As hemp becomes legal in more countries, we see a tremendous opportunity for a branded consumer packaged goods platform focused on beauty, beverages, and wellness in selected markets,” said Mr. Soqui. “With a focus on high quality products that are legally compliant, tested and safe, and developing a broad global distribution platform, both wholesale and online, we believe that we will be well positioned to develop brand recognition globally.”

Mr. Roth has 25 years of experience owning consumer packaged goods and medical device companies that have operated internationally, and is respected for his strategic leadership and disciplined approach to driving revenue.

“The European beverage market has very attractive business and financial dynamics given the recent legalization of hemp-infused beverages in the United Kingdom and other parts of Europe,” said Mr. Roth. “Asia is also a very attractive market for us. Our partnerships with major distribution partners and key opinion leaders will enable us to reach hundreds of millions of consumers very effectively.”

About Hempyre

Hempyre is an emerging global provider of branded hemp-formulated consumer packaged goods focused on Beauty, Beverage, and Wellness. Hempyre’s Beauty product line focuses on consumer hemp-formulated topical solutions to protect and rejuvenate their skin and body. Hempyre’s Beverage product line focuses on consumers who are looking for healthy ways in which to consume hemp-formulated distilled alcoholic and non-alcoholic spirits, sparkling and live sodas, pressed juices, water, and other ready-to-drink offerings. Hempyre’s Wellness product line focuses on consumers looking for hemp-derived CBD and CBG alternatives to treat anxiety, inflammation, insomnia, pain, or to manage and regulate their overall health.

Hempyre’s core strategy focuses on product branding and distribution in Europe, China, the U.S., and the Asia-Pacific region, while outsourcing most aspects of raw material production and finished goods manufacturing. Hempyre currently has 11 brands with more than 150 product SKUs across its three product segments. Hempyre’s hemp-formulated products are non-psychoactive and are made from high quality strains of hemp oil extracts containing either pure CBD or CBG, or combined with a broad or full spectrum of hemp compounds, including other cannabinoids and terpenes.

Hempyre’s primary operating subsidiaries are located in London, England, and Portland, Oregon, with additional staff in Hong Kong, and Auckland, New Zealand. With its licenses and permits, and given the emerging legalization of hemp-formulated products, Hempyre exports selected hemp-formulated CBD and CBG products from the U.S. to selected developed countries globally. Hempyre’s U.S. operations are licensed as a hemp handler by the Oregon Department of Agriculture, and act as a base for distribution throughout the U.S., with shipment enabled by the USPS. For raw material production and finished goods manufacturing, Hempyre’s strategy is to rely on farmers and concentrate processors in the U.S. for raw materials, and GMP-certified co-packers and white-label manufacturers for finished goods assembly or production. Hempyre’s hemp-formulated CBD and CBG products are distributed through its global network of distributors and wholesalers, its own and third-party owned e-commerce websites, Company-leased storefronts, and a variety of brick and mortar mainstream retailers. For more information visit www.hempyre.com.

Strategic Opportunities:

Hempyre is interested in discussing potential acquisitions of branded product and/or distribution companies in the Beauty, Beverage, or Wellness segments that could infuse CBD and CBG into their products.

Please contact jason@hempyre.com for information.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

U.S. Media Contact:
Mr. Erik Ritchie
media@hempyre.com
888-743-6797

U.K. Media Contact:
Mr. William Draper
media@hempyre.com
+44 (0) 800 020 9806

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sai Life Sciences Opens Dedicated Facility for Veterinary APIs in Bidar, India18.9.2025 19:22:00 EEST | Press release

Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of Unit VI, a dedicated facility for Veterinary Active Pharmaceutical Ingredient (API) production, in Bidar, India. Located alongside Unit IV, the company’s flagship API manufacturing site, Unit VI has been established exclusively for veterinary APIs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918612071/en/ Sai Life Sciences’ Veterinary APIs Unit in Bidar, India. The new facility is designed to meet the highest standards of safety, sustainability, and regulatory compliance, ensuring the production of high-quality APIs for veterinary applications. With this expansion, Sai Life Sciences aims to provide efficient and scalable manufacturing solutions to leading global animal health companies. Making the announcement, Krishna Kanumuri, CEO & Managing Direct

Celltrion Announces Commercial Availability of Omlyclo™ Across Europe at EADV 202518.9.2025 18:45:00 EEST | Press release

Celltrion, Inc. today showcased its longstanding commitment to expanding its biosimilar portfolio in the field of immuno-dermatology by attending the 2025 European Academy of Dermatology and Venereology (EADV) Congress, held 17-20 September in Paris, France. Following the European Commission (EC) approval of Omlyclo™, the first and only omalizumab biosimilar in Europe in May 2024, Omlyclo™ will be commercially available starting in Norway, with subsequent rollouts in European countries. As part of Celltrion’s mission to advance knowledge and understanding in dermatology, especially in chronic spontaneous urticaria (CSU), the company hosted satellite symposium presenting the results of the global Phase III clinical trial of Omlyclo™. The global Phase III clinical trial involved 619 patients with CSU, following them up to week 40. Patients were randomized to receive 300 mg or 150 mg of Omlyclo™, or reference product, every 4 weeks. Starting from week 12, patients who received Omlyclo™ we

Setting the Standard: AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’18.9.2025 17:40:00 EEST | Press release

AMRA Medical is proud to share its inclusion in the World’s Top HealthTech Companies list, published today by TIME in collaboration with Statista. This recognition positions AMRA among an elite group of global innovators that are leading healthcare transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918372780/en/ AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’ The selection, which comes just one week after celebrating AMRA’s 15 years of progress and innovation within the body composition space, highlights AMRA’s long-standing commitment to becoming a global leader in health informatics. By delivering detailed, reproducible insights within fat distribution and muscle composition, AMRA’s MRI-based technology is helping clinicians, researchers, and healthcare organizations unlock new levels of understanding across the metabolic and musculoskeletal sectors. “Being recognized by

illumynt, a CNE Direct Company, Is Pleased to Announce the Promotion of Jörg Herbarth to Chief Executive Officer (CEO)18.9.2025 17:30:00 EEST | Press release

illumynt, a CNE Direct company, is pleased to announce the promotion of Jörg Herbarth to Chief Executive Officer (CEO). Jörg has been a key member of illumynt’s executive leadership team since joining in June 2022, most recently serving as Chief Operating Officer. In his new role as CEO, Jörg will spearhead illumynt’s mission to become the number one provider of AI- and data-centric IT Asset Disposition (ITAD) solutions worldwide. Paul Knight, illumynt’s current CEO, will transition to the role of Founder & Chairman. In this capacity, Paul will continue to support the executive team with strategic guidance, while Jörg assumes full leadership of day-to-day operations and global expansion initiatives. Mr. Knight had come out of retirement a year ago to undertake some new initiatives and advance the company's strategic direction. With some necessary changes having taken place- he is thrilled to facilitate this transition to a reduced role again. Under Jörg’s leadership, illumynt will cont

Textron Aviation Broadens Aftermarket Connectivity Solutions for Cessna Citation Latitude by Offering Starlink High-Speed Internet18.9.2025 16:30:00 EEST | Press release

Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced an additional high-speed internet connectivity solution for the Cessna Citation Latitude following the Federal Aviation Administration’s (FAA) issuance of AeroMech’s Supplemental Type Certificate (STC) for Starlink high-speed internet connectivity. AeroMech’s STC utilizes Starlink’s constellation of Low Earth Orbit (LEO) satellites to provide more reliable connectivity over land, water and remote areas, where traditional in-flight Wi-Fi may not have service. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918380069/en/ Textron Aviation broadens aftermarket connectivity solutions for Cessna Citation Latitude by offering Starlink high-speed internet (Photo Credit: Textron Aviation) “With Starlink connectivity now available as an upgrade, Citation Latitude customers can enjoy a seamless, high-speed in-flight experience that keeps them connected in more

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye